Advice and guides to help improve your finances!
Frank Yan
New York University, Doctor of Philosophy, Structural Chemistry
Fudan University, Bachelor of Science, Physics
Dr. Frank Yan joined 3E Bioventures Capital as Venture Partner in 2018, and is also the General Manager of N.B. Quadriga, a joint venture biotechnology company discovering and developing innovative drugs for oncology. 
Dr. Yan has 15 years of pharmaceutical R&D, management, and operation experience in both U.S. and China covering key stages of the drug discovery process, with broad experience in various disease areas such as oncology, infectious diseases, neurodegenerative diseases, pain, ophthalmology, and metabolic diseases.  He co-invented two small molecule first-in-class investigational new drugs now in clinical development for the treatment of hepatitis B.
Dr. Frank Yan has broad project leadership experience for both biologics and small molecule projects, as well as deep and extensive experience in external innovation sourcing, in/out-licensing opportunity evaluation, transaction, and alliance management with over 30 deals signed or progressed at various stages.
From 2017 to 2018, Dr. Yan was responsible for External Alliance and Partnership of GSK Global Neurosciences Therapeutic Area.  He was with Roche R&D China from 2008 to 2016, taking various roles, including Head of External Alliance, Leader of Roche Innovation Center China New Facility (136 million CHF investment) User Team, members of Roche Global Small Molecule Research Extended Leadership Team, Roche Infectious Diseases Discovery and Translational Area Research Review Committee and Portfolio Committee, Roche China Management Team, and Head of Molecular Design and Chemical Biology.  From 2003 to 2008, Dr. Frank was Research Investigator II at Novartis in U.S. 
Dr. Frank Yan has close to 50 publications and patents including invited reviews and high profile papers in Nature, Science, Nature Structural and Molecular Biology, Molecular Cell, Nature Methods, PNAS.